PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines

NCT07013279 · Phase 3 · Not Yet Recruiting

PHASEPhase 3
STATUSNot Yet Recruiting
ENROLLMENT324
EST. COMPLETION2025-12-31

Conditions

Glabellar Lines

Interventions

DWP712 inj.Botox® 100 Units

Study details

SPONSORDaewoong Pharmaceutical Co. LTD.
START DATE2025-07-15

Related company profiles

Daewoong Pharmaceutical

069620.KS

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT07013279
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record